CONFERENCE UPDATE: ASH 2023

ALR triple regimen elicits a high CR rate among patients with treatment-naïve MCL and allows treatment de-escalation with real-time RMD monitoring

HEMATOLOGY
08 Mar 2023

Get access to our exclusive articles.
Related Articles

SHINE: Primary results of ibrutinib in combination with bendamustine-rituximab and rituximab maintenance in untreated MCL
HEMATOLOGY ONCOLOGY
29 Jul 2022

Bruton’s tyrosine kinase inhibitors delay disease progression and extend survival in patients with relapsed/refractory mantle cell lymphoma

Mantle cell lymphoma (MCL) is a B cell malignancy that is typically clinically aggressive with a poor prognosis.1 When MCL patients progress into relapsed/refractory MCL (RRMCL), the median overall survival (OS) is usually reduced to around 1 year. Currently, three Bruton’s tyrosine kinase inhibitor
HEMATOLOGY ONCOLOGY
30 Dec 2020

Optimizing therapy in mantle cell lymphoma

Mantle cell lymphoma (MCL) is an uncommon but aggressive subtype of lymphoid malignancy, generally considered to have a poor prognosis.1 Although the disease responds well to initial treatment, relapse will inevitably occur,1
HEMATOLOGY ONCOLOGY
28 Feb 2019